blackjack
There is now a clear pathway to Phase III and regulatory approval. CVAC Phase IIb trial commenced in mid-2010 and it is now merging into an 800-patient Phase III, to be conducted mainly in Europe from mid-2011.
Ordinarily a drug or medical device requires two Phase III trials before it can apply for FDA approval. However PRR guidance from the FDA is that CVac IIb and III trials will be sufficient for this product. We expect this Phase III to help put CVac on the market by 2014 or 2015.
http://www.primabiomed.com.au/investor/analyst_reports_pdf/Prima20110519.pdf
- Forums
- ASX - By Stock
- IMM
- reply from martin rogers re dubai release
reply from martin rogers re dubai release, page-38
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
28.5¢ |
Change
-0.005(1.72%) |
Mkt cap ! $413.9M |
Open | High | Low | Value | Volume |
29.0¢ | 29.5¢ | 28.0¢ | $1.441M | 5.001M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 102393 | 28.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
29.0¢ | 14707 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 102393 | 0.285 |
13 | 285561 | 0.280 |
13 | 499761 | 0.275 |
19 | 419400 | 0.270 |
6 | 127774 | 0.265 |
Price($) | Vol. | No. |
---|---|---|
0.290 | 14707 | 1 |
0.295 | 116416 | 4 |
0.300 | 121711 | 4 |
0.305 | 10000 | 1 |
0.310 | 249310 | 6 |
Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO & MD
Anthony Noble
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online